BMS 823778

Drug Profile

BMS 823778

Alternative Names: BMS823778

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Antihyperlipidaemics
  • Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Aug 2013 Bristol-Myers Squibb terminates a phase II trial for Hypertension (in overweight and obese patients) early in recruitment in the US, the EU and Latin America (NCT01602367)
  • 15 Jul 2013 Bristol-Myers Squibb withdraws a phase II trial for Artherosclerosis prior to enrolment (NCT01666704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top